Phase I Study of [111In]-FPI-2107 in EGFR Mutation-positive NSCLC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
12estimated
Sites
3
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-27 | actual | When the study began enrolling |
| Primary completion | 2026-07-21 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-21 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- EGFR Mutation-positive NSCLC
Interventions
- Drug: [111In]-FPI-2107
- Drug: FPI-2053
Primary outcomes
what the primary-completion date above is the date OFSafety and tolerability of [111In]-FPI 2107 following the administration of FPI 2053
measured From the screening period to 21 days after dosing
Dosimetry parameter of [111In]-FPI 2107 following the administration of FPI 2053
measured During the Imaging period (Day1 - Day4/5)
Dosimetry parameter of [111In]-FPI 2107 following the administration of FPI 2053
measured During the Imaging period (Day1 - Day4/5)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed